Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Stibler H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029–37.10.1093/clinchem/37.12.2029Search in Google Scholar
2. Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22–42.10.1111/j.1365-2141.2009.07807.xSearch in Google Scholar
3. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.10.1056/NEJMoa054494Search in Google Scholar
4. Burtis CA, Ashwood ER, Bruns DE, Tietz NW, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis, Mo: Saunders; 2013:553.Search in Google Scholar
5. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48.10.1016/S1470-2045(14)70442-5Search in Google Scholar
6. Cole C, Petree LE, Phillips JP, Shoemaker JM, Holdsworth M, Helitzer DL, et al. “Ethical responsibility” or “a whole can of worms”: differences in opinion on incidental finding review and disclosure in neuroimaging research from focus group discussions with participants, parents, IRB members, investigators, physicians and community members. J Med Ethics 2015;41:841–7.10.1136/medethics-2014-102552Search in Google Scholar PubMed
7. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med Off J Am Coll Med Genet 2013;15:565–74.10.1038/gim.2013.73Search in Google Scholar PubMed PubMed Central
8. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–7.10.1182/blood-2005-03-1038Search in Google Scholar PubMed PubMed Central
9. Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. J Am Med Assoc Oncol 2015;1:168–17.10.1001/jamaoncol.2015.23Search in Google Scholar PubMed
10. Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-medicare population analysis. Clin Lymphoma Myeloma Leuk 2015;15:177–86.e4.10.1016/j.clml.2014.09.004Search in Google Scholar PubMed PubMed Central
©2017 Walter de Gruyter GmbH, Berlin/Boston
